Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07111507) titled 'A Study of Tarlatamab for People With Prostate Cancer' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Metastatic Prostate Cancer
Intervention:
Drug: Tarlatamab
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: July 31, 2025
Target Sample Size: 32
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07111507
Published by HT Digital Content Services...